ESMO Breast 2021 | Optimal chemotherapy combinations in TNBC gBRCA subtypes
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, shares a summary of his talk on the optimal adjuvant and neoadjuvant chemotherapy combinations for the treatment of triple-negative breast cancer (TNBC), highlighting differences in the treatment of subtypes with or without germline BRCA (gBRCA). Prof. Kim outlines the role of pathological complete response (pCR) as a predictive marker and comments on the use of platinum-based chemotherapy and PARP inhibitors. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.
Disclosures
Sung-Bae Kim, MD, PhD, has received research funding from Novartis, Sanofi-Aventis, and DongKook Pharm Co; has participated as a consultant in advisory boards for Novartis, AstraZeneca, Lilly, Dae Hwa Pharmaceutical Co. Ltd, ISU Abxis, and Daiichi-Sankyo; and has stocks in Genopeaks and NeogeneTC.
